The Latest Eczema Industry Statistics Explained
Eczema affects over 31% of people in the United States.
The statistic that eczema affects over 31% of people in the United States indicates the prevalence of this inflammatory skin condition within the population. Eczema, also known as atopic dermatitis, is a common condition characterized by red, itchy, and inflamed skin. Affecting nearly a third of the population in the United States, this statistic highlights the significant impact of eczema on individuals’ quality of life and the healthcare system. Given the high prevalence rate, it is crucial for healthcare providers to be knowledgeable about eczema management and for public health efforts to focus on raising awareness, promoting early diagnosis, and implementing effective treatment strategies to improve the well-being of those affected by this condition.
The global eczema therapeutics market was valued at US$ 6,209.6 million in 2017.
This statistic states that the global eczema therapeutics market had a total value of US$ 6,209.6 million in the year 2017. This figure represents the total revenue generated by the sales of eczema treatment products and medications worldwide during that year. The market value indicates the size and financial significance of the eczema therapeutics industry, highlighting the demand for such products and the extent of the market’s economic impact. Analyzing this statistic can provide insights into trends in the treatment of eczema, the effectiveness of current therapies, as well as opportunities for growth and innovation in this sector.
The eczema therapeutics market is expected to rise to US$ 7,618.23 million by 2026.
This statistic indicates that the eczema therapeutics market, which refers to the industry focused on developing and selling products to treat eczema, is projected to experience significant growth over the next few years. Specifically, the market is expected to reach a value of US$ 7,618.23 million by the year 2026. This growth forecast suggests an increasing demand for eczema treatment options, potentially driven by factors such as a higher prevalence of eczema cases, advancements in medical research and technology, and a growing awareness of the condition among both healthcare professionals and consumers. The rising market value also points towards opportunities for pharmaceutical companies, healthcare providers, and other stakeholders to innovate and expand their offerings in this therapeutic area to meet the rising demand for eczema treatments.
Approximately 9.6 million children in the U.S. have eczema.
The statistic “Approximately 9.6 million children in the U.S. have eczema” represents the estimated number of children in the United States affected by the skin condition known as eczema. Eczema is a chronic inflammatory skin condition that can cause redness, itching, and dryness of the skin. The prevalence of eczema in children is quite high, with nearly 1 in 10 children estimated to be affected by the condition. This statistic highlights the significant burden that eczema places on children and their families, as it can lead to discomfort, reduced quality of life, and in some cases, additional health complications. Understanding the prevalence of eczema in children is crucial for healthcare providers, researchers, and policymakers to develop effective strategies for prevention, diagnosis, and treatment of this common skin condition.
Eczema affects 1 in 5 infants but only around 1 in 50 adults.
This statistic indicates a notable difference in the prevalence of eczema between infants and adults. Specifically, it suggests that eczema is more commonly observed in infants, with approximately 1 in 5 infants being affected by the condition. In contrast, eczema is much less common among adults, with only around 1 in 50 adults experiencing the condition. This disparity highlights how the incidence of eczema varies across different age groups, with infants being more susceptible to the condition compared to adults. Factors such as immature skin barrier function in infants and potential hormonal or environmental influences in adults may contribute to these differences in eczema prevalence between the two age groups.
China held the largest share in the Asia Pacific eczema therapeutics market in 2020.
This statistic indicates that China accounted for the highest proportion of the total market for eczema therapeutics in the Asia Pacific region in 2020. This suggests that China has a dominant presence in the eczema treatment market compared to other countries in the region. Factors contributing to China’s large share may include its significant population size, increasing healthcare infrastructure, growing awareness of eczema, and potentially higher rates of the condition within the population. This information is valuable for pharmaceutical companies, healthcare providers, and policymakers seeking to understand market dynamics and opportunities in the eczema therapeutics sector within the Asia Pacific region.
North America is the largest market for eczema treatment due to an increasing geriatric population.
The statistic states that North America is the largest market for eczema treatment, driven by a growing elderly population in the region. This suggests that the prevalence of eczema is higher among older individuals in North America compared to other regions, leading to a higher demand for eczema treatment products and services. As people age, their skin tends to become more sensitive and susceptible to skin conditions like eczema, thereby driving the need for effective treatments. The statistic highlights the importance of understanding demographic trends and their impact on the healthcare market for specific conditions like eczema, as it can help inform healthcare providers, policymakers, and pharmaceutical companies in addressing the needs of this population segment.
Europe is anticipated to be the second-largest market for eczema treatment.
This statistic suggests that Europe is expected to have the second-highest demand for products or services related to the treatment of eczema, a common skin condition characterized by inflammation and itchiness. The anticipated high market demand in Europe indicates a significant prevalence of eczema cases in the region, leading to a growing need for effective treatment options. Factors such as increasing awareness of eczema, changing lifestyle patterns, and advancements in medical research and technology may be contributing to this projection. The statistic highlights the importance of addressing eczema as a healthcare concern in Europe and presents opportunities for companies in the healthcare and pharmaceutical industries to cater to the growing market of eczema treatment in the region.
In 2019, topical therapies accounted for a 60% share of the global atopic dermatitis drugs market.
The statistic indicates that in 2019, topical therapies comprised 60% of the global market for drugs targeted at treating atopic dermatitis. This suggests that topical treatments, which are applied directly to the skin, were the dominant category of medications used for managing atopic dermatitis worldwide during that time period. The considerable market share held by topical therapies highlights their importance and popularity among healthcare providers and patients for treating this chronic inflammatory skin condition characterized by red, itchy rashes. This statistic underscores the significant role that topical treatments play in the management of atopic dermatitis compared to other types of medications such as oral or injectable drugs.
Dupixent, a drug for severe atopic dermatitis, had global sales of $2.316 billion in 2019.
The statistic indicates that Dupixent, a pharmaceutical drug designed to treat severe atopic dermatitis, generated global sales amounting to $2.316 billion in the year 2019. This figure highlights the significant commercial success and widespread adoption of Dupixent for the treatment of this particular skin condition on a global scale. The substantial revenue generated suggests a high demand for the drug and underscores its effectiveness in addressing the medical needs of individuals suffering from severe atopic dermatitis. The sales figure also reflects the potential market size and economic value of pharmaceutical products targeting specific medical conditions.
The most common form of eczema, Atopic Dermatitis, affects around 15% of children and 2% of adults.
The statistic indicates that Atopic Dermatitis, which is the most common form of eczema, has varying rates of prevalence among different age groups. Specifically, around 15% of children are affected by Atopic Dermatitis, while only about 2% of adults are affected. This suggests that this particular type of eczema primarily impacts children at a higher rate than adults. The disparity in prevalence rates between children and adults may be attributed to factors such as the natural course of the condition, differences in immune system function, and environmental triggers. Understanding these prevalence rates can help healthcare providers and researchers better tailor treatment and preventative measures for Atopic Dermatitis in different age groups.
Biologic treatment is expected to contribute to significant growth in the eczema treatment market.
This statistic indicates that biologic treatment, a type of medical intervention derived from living organisms, is anticipated to play a substantial role in driving growth within the market for treating eczema, a chronic skin condition characterized by inflammation and itching. Biologic treatments are known for their ability to target specific pathways in the immune system that are involved in causing eczema, potentially offering more effective and targeted therapy compared to traditional treatments. As a result, the increasing adoption and advancements in biologic therapies are expected to lead to notable expansion and innovation in the eczema treatment market, offering new opportunities for managing and improving outcomes for individuals affected by this skin disorder.
Asia-Pacific’s eczema therapeutics market is projected to grow at the highest CAGR between 2018-2023.
The statistic indicates that the Asia-Pacific region’s market for eczema therapeutics is expected to experience the highest Compound Annual Growth Rate (CAGR) in the period spanning from 2018 to 2023. This suggests that the demand for eczema treatments in the Asia-Pacific region is forecasted to increase at a faster pace compared to other regions during this timeframe. Factors contributing to this growth could include rising awareness of eczema, improving healthcare infrastructure, increasing disposable income in the region, and a growing focus on preventive healthcare measures. Companies operating in the eczema therapeutics market may find opportunities for expansion and market penetration in the Asia-Pacific region due to its projected strong growth potential.
The global prevalence of atopic eczema is approximately 230 million.
The statistic stating that the global prevalence of atopic eczema is approximately 230 million indicates the estimated number of individuals worldwide who are affected by this chronic and inflammatory skin condition. Atopic eczema, also known as atopic dermatitis, is characterized by symptoms such as redness, itching, and skin inflammation, which can significantly impact the quality of life for those affected. This statistic highlights the widespread nature of atopic eczema and underscores the importance of public health efforts to address the condition and improve treatment options for individuals dealing with this skin disorder on a global scale.
Work-hour loss due to atopic dermatitis in the U.S. adds an estimated $563 million to the direct costs associated with the disease.
This statistic highlights the significant economic impact of atopic dermatitis in the United States in terms of work-hour losses. Atopic dermatitis, a common chronic inflammatory skin condition, is estimated to contribute $563 million to the direct costs associated with the disease due to reduced productivity and missed work hours. Work-hour loss is a key component of the economic burden imposed by atopic dermatitis, illustrating how the condition not only affects individuals’ quality of life but also has tangible financial repercussions both for individuals and the healthcare system. This statistic underscores the importance of addressing atopic dermatitis comprehensively to not only improve patient outcomes but also mitigate the economic burden associated with the disease.
The market for pediatric eczema treatment is expected to reach $18.4 billion in 2030.
The statistic suggests that the market for pediatric eczema treatment is projected to grow significantly in terms of monetary value, reaching $18.4 billion by the year 2030. This growth indicates a rising demand for treatment options for pediatric eczema, likely due to an increasing prevalence of the condition and the need for effective remedies. The forecasted market size reflects the potential economic opportunities within the pediatric eczema treatment sector, highlighting the importance of addressing this particular health concern in the coming decade. The statistic also signifies potential investment opportunities for pharmaceutical companies, healthcare providers, and researchers looking to innovate and expand in the field of pediatric dermatology.
Conclusion
The statistics presented in this blog post shed light on the prevalence and impact of eczema within the healthcare industry. By understanding the scope of this skin condition and its effects on individuals, healthcare professionals and researchers can better advocate for improved treatment options and management strategies for those affected by eczema.
References
0. – https://www.www.ncbi.nlm.nih.gov
1. – https://www.www.technavio.com
2. – https://www.www.globenewswire.com
3. – https://www.www.coherentmarketinsights.com
4. – https://www.www.statista.com
5. – https://www.www.allergyuk.org
6. – https://www.www.futuremarketinsights.com
7. – https://www.www.business-standard.com
8. – https://www.www.nationaleczema.org
